ERBB2 and breast cancer: Trastuzumab-based therapy for HER2+ BC was soon added in the neoadjuvant setting with increased efficacy, while dual blockade of the HER2 receptor with pertuzumab/trastuzumab combined with docetaxel was significantly associated with better pCR rates [2].